Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer

被引:49
作者
Abou-Jawde, RM
Mekhail, T
Adelstein, DJ
Rybicki, LA
Mazzone, PJ
Caroll, MA
Rice, TW
机构
[1] Cleveland Clin Fdn, Taussig Canc Ctr, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Taussig Canc Ctr, Dept Biostat, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Taussig Canc Ctr, Dept Pulm Allergy & Crit Care Med, Cleveland, OH 44195 USA
[4] Cleveland Clin Fdn, Taussig Canc Ctr, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA
关键词
diffusion capacity of the lung for carbon monoxide; esophageal cancer; postoperative acute respiratory complication; pulmonary function; radiation therapy;
D O I
10.1378/chest.128.1.250
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: To evaluate the effects of induction concurrent chemoradiotherapy (cCRT) on pulmonary function and postoperative acute respiratory complications (PARCs). Design: A retrospective review of our patients treated with induction cCRT to determine the impact on pulmonary function and identify predictors of PARCs. Correlations were sought between patient demographics, clinical characteristics, pre-cCRT and post-cCRT pulmonary function, radiotherapy dose, chemotherapy agents, and the development of PARCs. Participants: One hundred fifty-five patients treated in three separate clinical trials were identified; 47 patients received 30 Gy (150 cGy bid) of radiation concurrently with a single course of cisplatin/5-fluorouracil (5FU), and 108 patients received 45 Gy (150 cGy bid in a split course) concurrent with two courses of either cisplatin/5FU (n = 69) or cisplatin/paclitaxel (n = 39). Esophagectomy was performed in 141 of these 155 patients following CCRT. Results: cCRT was only associated with significant worsening of the diffusion capacity of the lung for carbon monoxide (DLCO), which decreased a median of 21.7% in the 45-Gy group (p = 0.007), and 8.6% in the 30-Gy group (p = 0.07). This DLCO decrease was statistically greater in the 45-Gy group than in the 30-Gy group (p = 0.02). PARCs developed in 18 patients. Percentage of predicted FEVI and FVC, both before and after cCRT, were both significantly higher in patients without PARCs than in patients with PARCs (p = 0.031 and p 0.010, respectively). Post-cCRT DLCO was also significantly worse in patients with PARCs (p = 0.002). PARCs occurred significantly more often among those treated with 45 Gy (17 of 102 patients) compared to those treated with 30 Gy (1 of 39 patients) [p = 0.025]. In the 18 patients with PARCs, the median survival was only 2.1 months. This was significantly less than the 16.4-month median survival in the 123 patients who did not have PARCs (p = 0.001). Conclusions: In patients treated with induction cCRT, higher radiation doses result in increasing impairment of gas exchange. PARCs were more likely in those patients with lower lung volumes, lower post-cCRT DLCO, and in those receiving higher radiation doses. These acute respiratory complications were also associated with a significant reduction in patient survival.
引用
收藏
页码:250 / 255
页数:6
相关论文
共 35 条
[1]  
Adelstein DJ, 1997, CANCER-AM CANCER SOC, V80, P1011
[2]   Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy [J].
Adelstein, DJ ;
Rice, TW ;
Rybicki, LA ;
Larto, MA ;
Ciezki, J ;
Saxton, J ;
DeCamp, M ;
Vargo, JJ ;
Dumot, JA ;
Zuccaro, G .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2032-2039
[3]  
ADELSTEIN DJ, 2003, P AN M AM SOC CLIN, V22, P273
[4]  
Adham M, 2000, CANCER, V89, P946
[5]  
[Anonymous], 1996, ARCH SURG-CHICAGO, V131, P824, DOI DOI 10.1001/ARCH-SURG.1996.01430200029005
[6]   Pulmonary complications after Esophagectomy [J].
Avendano, CE ;
Flume, PA ;
Silvestri, GA ;
King, LB ;
Reed, CE .
ANNALS OF THORACIC SURGERY, 2002, 73 (03) :922-926
[7]  
Bancewicz J, 2002, LANCET, V359, P1727
[8]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[9]  
BRAUNWALD EFA, 2001, HARRISONS PRINCIPLES, P1523
[10]   Resectable esophageal carcinoma: Local control with neoadjuvant chemotherapy and radiation therapy [J].
Chidel, MA ;
Rice, TW ;
Adelstein, DJ ;
Kupelian, PA ;
Suh, JH ;
Becker, M .
RADIOLOGY, 1999, 213 (01) :67-72